Further stratification of patients with multiple myeloma by International Staging System in combination with ratio of serum free κ to λ light chains

Leukemia and Lymphoma

Volumn 54, Issue 1, 2013, Pages 123-132

  Xu, Yan ^a   Sui, Weiwei ^a   Deng, Shuhui ^a   An, Gang ^a   Wang, Yafei ^b   Xie, Zhenqing ^a   Yao, Hongjing ^a   Zhu, Guoqing ^a   Zou, Dehui ^a   Qi, Junyuan ^a   Hao, Mu ^a   Zhao, Yaozhong ^a   Wang, Jianxiang ^a   Chen, Tao ^a   Qiu, Lugui ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Diagnosis; International Staging System; Multiple myeloma; Prognosis; Serum free light chains

Indexed keywords

ACICLOVIR; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; THALIDOMIDE; VINCRISTINE; ZOLEDRONIC ACID;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBODY DETECTION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CHINESE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOGLOBULIN BLOOD LEVEL; INTERNATIONAL STAGING SYSTEM; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84870895824     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.704033     Document Type: Article

References (39)

1. D ispenzieri A, Kyle R, Merlini G, et al.; International Myeloma Working Group. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009 ; 23: 215-224.
2. Offi dani M, Polloni C, Cavallo F, et al. Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma 2012 Mar 16. [Epub ahead of print]
3. Ghobrial IM, Munshi NC, Harris BN, et al. A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. Am J Hematol 2011; 86: 573-578.
4. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
5. Xu Y, Deng SH, Mai YJ, et al. The analysis of prognostic variables in 123 patients with multiple myeloma. Zhonghua Xue Ye Xue Za Zhi 2007; 28: 330-334.
6. Deng SH, Xu Y, Mai YJ, et al. Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients. Zhonghua Xue Ye Xue Za Zhi 2008; 29: 217-221.
7. Li Q, An G, Li CW, et al. The signifi cances of 13q14 deletion for development and prognosis of multiple myeloma. Zhonghua Xue Ye Xue Za Zhi 2011; 32: 217-220.
8. Jagannath S, Barlogie B, Berenson JR, et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 2005; 103: 1195-1200. (Pubitemid 40328090)
9. Tan D, Teoh G, Lau LC, et al. An abnormal nonhyperdiploid karyotype is a signifi cant adverse prognostic factor for multiple myeloma in the bortezomib era. Am J Hematol 2010; 85: 752- 756.
10. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47: 673-680. (Pubitemid 32275810)
11. M ö sbauer U, Ayuk F, Schieder H, et al. Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofi xation after allogeneic stem cell transplantation. Haematologica 2007; 92: 275- 276. (Pubitemid 46852439)
12. Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008; 111: 785- 789.
13. Drayson M, Tang LX, Drew R, et al. Serum free light chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97: 2900-2902.
14. Bradwell AR, Carr-Smith HD, Mead GP, et al. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003; 361: 489-491. (Pubitemid 36173716)
15. M ori S, C rawford B S, R oddy J V, et al. S erum free light chains in myeloma patients with an intact M protein by immunofi xation:potential roles for response assessment and prognosis during induction therapy with novel agents. Hematol Oncol 2011 Oct 26. [Epub ahead of print]
16. Hutchison CA, Cockwell P, Stringer S, et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol 2011; 22: 1129-1136.
17. Mao XB, Chen XQ, Zhai YP, et al. Measurement of serum free light chains and its clinical signifi cance in 20 newly diagnosed patients of multiple myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008; 16: 829-832.
18. Jung S, Kim M, Lim J, et al. Serum free light chains for diagnosis and follow-up of multiple myeloma. Korean J Lab Med 2008; 28: 169-173.
19. Kaplan B, Ramirez-Alvarado M, Dispenzieri A, et al. Isolation and biochemical characterization of plasma monoclonal free light chains in amyloidosis and multiple myeloma:a pilot study of intact and truncated forms of light chains and their charge properties. Clin Chem Lab Med 2008; 46: 335-341. (Pubitemid 351317768)
20. Shimizu K, Itoh J, Sugiura I, et al. Evaluation of the clinical relevance of serum measurements of free-light chains in patients with multiple myeloma. Rinsho Ketsueki 2006; 47: 303-309.
21. S thaneshwar P, N adarajan V, M aniam J A, et al. S erum free light chains: Diagnostic and prognostic value in multiple myeloma. Clin Chem Lab Med 2009; 47: 1101- 1107.
22. Durie BG, Harousseau JL, Miguel JS, et al. International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467- 1473. (Pubitemid 44264086)
23. de Larrea CF, Cibeira MT, Elena M, et al. Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands:implications for stringent complete remission defi nition. Blood 2009; 114: 4954-4956.
24. Singhal S, Vickrey E, Krishnamurthy J, et al. The relationship between the serum free light chain assay and serum immunofi xation electrophoresis, and the defi nition of concordant and discordant free light chain ratios. Blood 2009; 114: 38-39.
25. Mead GP, Carr-Smith HD, Drayson MT, et al. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004; 126: 348-354. (Pubitemid 39005714)
26. van Rhee F, Bolejack V, Hollmig K, et al. High serum-free light chain levels and their rapid reduction in response to therapy defi ne an aggressive multiple myeloma subtype with poor prognosis. Blood 2007; 110: 827-832. (Pubitemid 47267417)
27. Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, et al. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol 2007; 137: 240-243. (Pubitemid 46537637)
28. Dingli D, Kyle RA, Rajkumar SV, et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood 2006; 108: 1979-1983. (Pubitemid 44395010)
29. Rajkumar SV, Kyle RA, Th erneau T M, et al. S erum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined signifi cance. Blood 2005; 106: 812- 817. (Pubitemid 41076419)
30. Snozek CL, Katzmann JA, Kyle RA, et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma:proposed incorporation into the international staging system. Leukemia 2008; 22: 1933-1937.
31. D ispenzieri A, Z hang L, K atzmann J A, et al. A ppraisal of immunoglobulin free light chain as a marker of response. Blood 2008; 111: 4908-4915.
32. Khoriaty R, Hussein MA, Faiman B, Kelly M, Kalaycio M, Baz R. Prediction of response and progression in multiple myeloma with serum free light chains assay:corroboration of the serum free light chain response defi nitions. Clin Lymphoma Myeloma Leuk 2010; 10: E10YE13.
33. Kyrtsonis MC, Maltezas D, Tzenou T, et al. Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma. Semin Hematol 2009; 46: 110-117.
34. K yrtsonis M C, M altezas D, K oulieris E, et al. R esponse to bortezomib in refractory/relapsed multiple myeloma patients:a single center experience with discussion on specifi c issues. Asia Pac J Oncol Hematol 2010; 2: 29-39.
35. Kang Y, Liu H, Wang L, et al. [Th e clinical application of serum | / ⌊ light chain ratio and protein electrophoresis in the diagnosis of multiple myeloma]. Lab Med 2011; 26: 675- 678.
36. B oyd K D, R oss F M, C hiecchio L, et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS:analysis of patients treated in the MRC Myeloma IX trial. Leukemia 2012; 26: 349-355.
37. M ö sbauer U, Ayuk F, Schieder H, et al. Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofi xation after allogeneic stem cell transplantation. Haematologica 2007; 92: 275- 276. (Pubitemid 46852439)
38. Pratt G, Mead GP, Godfrey KR, et al. The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum-free light chains. Leuk Lymphoma 2006; 47: 21- 28. (Pubitemid 43101720)
39. Tate J, Mollee P, Gill D. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2005; 128: 405-406.